➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
Medtronic
Merck
McKinsey

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

Nabumetone - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for nabumetone and what is the scope of patent protection?

Nabumetone is the generic ingredient in two branded drugs marketed by Annora Pharma, Chartwell Molecules, Chartwell Rx, Copley Pharm, Impax Labs Inc, Invagen Pharms, Lgm Pharma, Mylan Pharms Inc, Nostrum Labs Inc, Oxford Pharms, Sandoz, Sciegen Pharms Inc, Watson Labs, and Smithkline Beecham, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for nabumetone. Twenty-six suppliers are listed for this compound.

Drug Prices for nabumetone

See drug prices for nabumetone

Drug Sales Revenue Trends for nabumetone

See drug sales revenues for nabumetone

Recent Clinical Trials for nabumetone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Federal University of São PauloPhase 4
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Stanley Medical Research InstitutePhase 2

See all nabumetone clinical trials

Pharmacology for nabumetone
Paragraph IV (Patent) Challenges for NABUMETONE
Tradename Dosage Ingredient NDA Submissiondate
RELAFEN TABLET;ORAL nabumetone 019583

US Patents and Regulatory Information for nabumetone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz NABUMETONE nabumetone TABLET;ORAL 075590-002 Feb 25, 2002 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Watson Labs NABUMETONE nabumetone TABLET;ORAL 091083-001 Jun 13, 2011 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Annora Pharma NABUMETONE nabumetone TABLET;ORAL 090445-002 Jan 12, 2011 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Sciegen Pharms Inc NABUMETONE nabumetone TABLET;ORAL 078420-002 Sep 24, 2008 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Mylan Pharms Inc NABUMETONE nabumetone TABLET;ORAL 090516-001 Jul 12, 2010 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for nabumetone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 ⤷  Try it Free ⤷  Try it Free
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 ⤷  Try it Free ⤷  Try it Free
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 ⤷  Try it Free ⤷  Try it Free
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-001 Dec 24, 1991 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
Medtronic
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.